



(51) International Patent Classification:

A61K 38/10 (2006.01) C07K 7/00 (2006.01)
A61K 38/08 (2006.01) C07K 16/00 (2006.01)
A61K 38/04 (2006.01) C07K 17/00 (2006.01)
C07K 5/00 (2006.01)

(21) International Application Number:

PCT/US2014/030352

(22) International Filing Date:

17 March 2014 (17.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/800,048 15 March 2013 (15.03.2013) US
61/800,284 15 March 2013 (15.03.2013) US

(71) Applicants: **PROTAGONIST THERAPEUTICS, INC.**
[US/US]; 521 Cottonwood Drive, Suite A, Milpitas, California 95035 (US). **ZEALAND PHARMA A/S** [DK/DK];
Smedeland 36, DK-2600 Glostrup (DK).

(72) Inventors: **SMYTHE, Mark Leslie**; 8 Morgan Terrace,
Bardon, Queensland 4065 (AU). **BOURNE, Gregory Thomas**;
29 Moolingal Street, Jindalee, Queensland 4074 (AU). **VINK, Simone**;
5/70 Swann Road, Taringa, Queensland 4068 (AU). **FREDERICK, Brian T.**;
8470 Glen Arbor Road, Ben Lomond, California 95005 (US). **MADALA, Praveen**;
55-Bilkurra Street, Middle Park, Brisbane, Queensland 4074 (AU). **TOFTENG SHELTON, Anne Pernille**;
Prisholmvej 40, DK-2500 Valby (DK). **FOG, Jacob Ulrik**;
Vaerebrovej 194, DK-2880 Bagsvaerd (DK).

(74) Agents: **NUDELMAN, Aaron S.** et al.; Cooley LLP, 1299
Pennsylvania Avenue NW, Suite 700, Washington, District
of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

12 February 2015

(54) Title: HEPCIDIN ANALOGUES AND USES THEREOF

(57) Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

